Condition: Resistant Hypertension · Sponsor: DeepQure Inc.
HQ-HTN-G01 is a prospective, multicenter, single arm, open label, early feasibility study to evaluate initial safety and device design concept of "HyperQureTM RDN System", laparoscopic renal denervation therapy, in patients with resistant hypertension on three(3) or more antihypertensive medications
This description comes directly from the study's public registry record.
Aeyoung Woo · 82 10 7109 0205 · aywoo@deepqure.com
Jaehung Jung, MD · 82 10 8885 4689 · jhjung@deepqure.com
Always discuss trial participation with your own doctor first.
| University of California Irvine | Orange, California, United States | Recruiting |
| Stanford Health Care | Stanford, California, United States | Recruiting |
| University of Florida College of Medicine | Gainesville, Florida, United States | Recruiting |
| Henry Forth Health | Detroit, Michigan, United States | Recruiting |
| Mayo Clinic | Rochester, Minnesota, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06526858